GlassScriptPhysician profile
Lela Lankerani
NPI 1710159140
$13,129.99
in general payments reported to CMS, 2019-2025
33 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,905 · 2020: $912 · 2021: $1,840 · 2022: $2,430 · 2023: $2,606 · 2024: $1,744 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,939 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,939.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101.63 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,501.19 | 2019-2025 | |
| Janssen Biotech, INC. | $2,276.94 | 2019-2025 | Tremfya, Remicade, Stelara |
| Merz North America, INC. | $873.76 | 2019-2024 | |
| Pfizer INC. | $656.30 | 2019-2025 | |
| Amgen INC. | $627.31 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $591.37 | 2019-2025 | |
| Biofrontera INC. | $568.24 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $481.76 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $458.60 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $429.83 | 2019-2022 | |
| Almirall LLC | $369.06 | 2022-2025 | Seysara, Klisyri |
| Galderma Laboratories, L.P. | $340.27 | 2019-2025 | Aklief, Twyneo, Oracea |
| Ucb, INC. | $335.19 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $324.63 | 2022-2025 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $313.80 | 2022-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $289.84 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $287.43 | 2019-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $182.49 | 2019-2024 | Libtayo |
| Epi Health, LLC | $181.73 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.76 | 2019-2024 | Cabtreo |
| Vyne Pharmaceuticals INC. | $138.39 | 2021 | |
| Revance Therapeutics, INC. | $133.46 | 2025 | Daxxify |
| Journey Medical Corporation | $121.68 | 2019-2023 | |
| Allergan, INC. | $103.43 | 2020-2022 | |
| Prugen, INC. Pharmaceuticals | $87.52 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $67.12 | 2020-2025 | |
| Dermavant Sciences, INC. | $67.11 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $52.73 | 2023-2024 | Zoryve |
| Botanix Sb INC | $37.92 | 2025 | Sofdra |
| Organon LLC | $33.54 | 2025 | Nexplanon, Vtama |
| Aclaris Therapeutics, INC. | $19.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.83 | 2022 | |
| Dermira, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lela Lankerani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.